GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius Stedim Biotech SA (STU:56S1) » Definitions » Debt-to-EBITDA

Sartorius Stedim Biotech (STU:56S1) Debt-to-EBITDA : 4.73 (As of Sep. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Sartorius Stedim Biotech Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sartorius Stedim Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €32 Mil. Sartorius Stedim Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €2,800 Mil. Sartorius Stedim Biotech's annualized EBITDA for the quarter that ended in Sep. 2024 was €598 Mil. Sartorius Stedim Biotech's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was 4.73.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Sartorius Stedim Biotech's Debt-to-EBITDA or its related term are showing as below:

STU:56S1' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.35   Med: 0.65   Max: 6.64
Current: 6.64

During the past 13 years, the highest Debt-to-EBITDA Ratio of Sartorius Stedim Biotech was 6.64. The lowest was 0.35. And the median was 0.65.

STU:56S1's Debt-to-EBITDA is ranked worse than
87.65% of 429 companies
in the Medical Devices & Instruments industry
Industry Median: 1.54 vs STU:56S1: 6.64

Sartorius Stedim Biotech Debt-to-EBITDA Historical Data

The historical data trend for Sartorius Stedim Biotech's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius Stedim Biotech Debt-to-EBITDA Chart

Sartorius Stedim Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 1.03 0.78 0.85 4.87

Sartorius Stedim Biotech Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.44 6.20 5.77 6.23 4.73

Competitive Comparison of Sartorius Stedim Biotech's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sartorius Stedim Biotech's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sartorius Stedim Biotech's Debt-to-EBITDA falls into.



Sartorius Stedim Biotech Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sartorius Stedim Biotech's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(79.1 + 3602.9) / 755.7
=4.87

Sartorius Stedim Biotech's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(32 + 2799.7) / 598.4
=4.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


Sartorius Stedim Biotech  (STU:56S1) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Sartorius Stedim Biotech Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sartorius Stedim Biotech's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sartorius Stedim Biotech Business Description

Address
Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech, or SSB, is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs, and has a focus on single-use technology, or SUT. It is a subsidiary of Sartorius AG, which has a 74% ownership and 85% voting control. The business is geographically diverse.

Sartorius Stedim Biotech Headlines

No Headlines